Article
Pharmacology & Pharmacy
Xiaomi Li, Jingyan Wang, Xiaoyan Ding, Yawen Xu, Minghua Yu, Hongxiao Wu, Na Deng, Wei Li, Jinglong Chen
Summary: The clinical efficacy of lenvatinib was compared between hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and hepatitis C virus (HCV)-related HCC. The study found that patients with HBV-HCC had higher objective response rate and disease control rate compared to HCV-HCC, but there were no significant differences in progression-free survival and overall survival between the two groups. Multivariate regression analysis identified HBV infection and antiviral time > 5 years as independent favorable factors for progression-free survival. Overall, lenvatinib seemed to be more effective in HBV-related HCC compared to HCV-related HCC.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Won-Mook Choi, Gi-Ae Kim, Jonggi Choi, Gwang Hyeon Choi, Yun Bin Lee, Dong Hyun Sinn, Young-Suk Lim
Summary: This study aimed to investigate the association between baseline HBV viral load and on-treatment HCC risk in patients with CHB without cirrhosis. The study found that patients with moderate baseline viral load had the highest HCC risk.
Article
Medicine, General & Internal
Junyi Shen, Weili Qi, Junlong Dai, Shusheng Leng, Kangyi Jiang, Yu Zhang, Shun Ran, Chuan Li, Tianfu Wen
Summary: This study compared the effects of tenofovir (TDF) and entecavir (ETV) on the recurrence of hepatocellular carcinoma (HCC) beyond the Milan criteria. The results showed that TDF treatment significantly reduced the risk of HCC recurrence compared to ETV therapy.
CHINESE MEDICAL JOURNAL
(2022)
Article
Oncology
Peng Wang, Xinhui Wang, Xiaoli Liu, Fengna Yan, Huiwen Yan, Dongdong Zhou, Lihua Yu, Xianbo Wang, Zhiyun Yang
Summary: This study aimed to assess the effect of primary non-response to antiviral therapy on the survival or prognosis of patients with HCC with a high load of HBV DNA. The results showed that primary non-response may shorten the median survival time of patients.
Review
Virology
Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo, Antonio Craxi
Summary: Hepatitis B virus (HBV) infection is associated with the risk of developing hepatocellular carcinoma (HCC), with or without liver cirrhosis, through various mechanisms. The molecular profile of HBV-HCC is constantly being studied, and it is the result of altered molecular pathways, changes in the microenvironment, and DNA damage. Proper management of HBV-related liver disease is crucial for prevention and treatment of HCC.
Article
Oncology
Meng Xue, Xiaona Lin, Qiu-Xiong Lin, Xiaoyong Pu, Jiumin Liu, Xing-Fang Li, Jun Hou, Xudong Liu, Ren Chen
Summary: This study found that HBV infection was associated with an increased risk of HCC compared to HEV infection, and that HEV infection may mitigate the promoting impact of HBV on HCC development.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Nicholas Noverati, Rukaiya Bashir-Hamidu, Dina Halegoua-DeMarzio, Hie-Won Hann
Summary: Hepatitis B virus is a significant cause of hepatocellular carcinoma globally. The complex mechanisms of this virus include interactions with the host's immune system. Factors such as stress can amplify these mechanisms. Chronic stress, harmful to health, can suppress or activate the host's defense system, leading to tumor initiation and progression in liver cancer. Chronic stress, often overlooked, should be recognized as a potential risk factor.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Gwang Hyeon Choi, Eun Sun Jang, Young Seok Kim, Youn Jae Lee, In Hee Kim, Sung Bum Cho, Han Chu Lee, Jeong Won Jang, Moran Ki, Hwa Young Choi, Dahye Baik, Sook-Hyang Jeong
Summary: Compared to untreated patients, those treated with IBT or DAA had significantly lower incidences of hepatocellular carcinoma and death/transplantation. There were no significant differences in the risks of HCC and death/transplantation between patients who achieved sustained virologic response with IBT or DAA.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Medicine, General & Internal
Ji Hun Lee, Seung Kak Shin, Seong Hee Kang, Tae Hyung Kim, Hyung Joon Yim, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Oh Sang Kwon, Soon Ho Um, Kwan Soo Byun
Summary: This study developed a precise and simple risk score model for predicting the development of hepatocellular carcinoma in patients with chronic hepatitis B. The model showed improved long-term prediction and provided three distinct risk categories for HCC.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, General & Internal
Mirjam B. Zeisel, Francesca Guerrieri, Massimo Levrero
Summary: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is largely caused by chronic hepatitis B virus (HBV) infection. While antiviral therapies can suppress viral replication, there is currently no cure for chronic HBV infection. HBV contributes to liver carcinogenesis through direct and indirect effects on host epigenetic alterations, modulating gene expression.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Summary: A novel risk-scoring model for predicting hepatocellular carcinoma development in treatment-naive patients with chronic hepatitis B virus infection starting antiviral therapy has been developed, showing better performance in Asian patients. This model is important for developing individualized surveillance methods.
Article
Gastroenterology & Hepatology
Jong-In Chang, Dong Hyun Sinn, Hyun Cho, Seonwoo Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Summary: More than half of AVT-naive patients experienced HBV reactivation within three years, which was associated with increased risk of overall mortality. The risk of HBV reactivation was lower for those receiving AVT, suggesting that prompt AVT needs to be considered for AVT naive HBV-related HCC patients with undetectable HBV DNA levels.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Hou-Ying Cheng, Rey-Heng Hu, Chih-Yang Hsiao, Ming-Chih Ho, Yao-Ming Wu, Po-Huang Lee, Cheng-Maw Ho
Summary: This study aimed to investigate the survival outcomes of antiviral agents in patients with hepatitis C virus who underwent liver resection for primary hepatocellular carcinoma. The results showed that antiviral treatment can prolong overall survival, and DAAs may have a protective effect against hepatic decompensation.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Oncology
Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Summary: Dynamic changes in fibrosis markers occur under long-term antiviral treatment for chronic hepatitis B. Lowering the on-treatment liver stiffness cutoff to 6.4 kPa is more predictive for hepatocellular carcinoma risk in patients receiving long-term antiviral treatment, compared to 12 kPa or cirrhosis on ultrasonography. Further studies are needed for validation.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2021)
Article
Gastroenterology & Hepatology
Hyun-seok Kim, Xian Yu, Jennifer Kramer, Aaron P. Thrift, Pete Richardson, Yao-Chun Hsu, Avegail Flores, Hashem B. El-Serag, Fasiha Kanwal
Summary: This study evaluated the performance of 10 HCC risk prediction models in patients with HBV, showing that most models performed well in predicting HCC risk and identified low-risk subsets for exclusion from HCC surveillance. Further research is needed to validate these findings.
JOURNAL OF HEPATOLOGY
(2022)
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.